Exin Therapeutics Analysis: $500K Raised
What is Exin Therapeutics?
Exin Therapeutics develops a discovery platform for genetic therapies targeting dysregulated neural circuits across disorders. Their neurotherapeutics utilize advancements in genetics and technology to create treatments for neurological disorders. The company focuses on gene therapy, nucleotide-based therapeutics, and cell-based therapies to address previously untreatable disease mechanisms.
Employees
1-10
Founded
2024
Industry
HealthTech, Biotech
YC Batch
W25
Product Features & Capabilities
- Gene therapy
- Nucleotide-based therapeutics
- Cell-based therapies
Use Cases
Target dysregulated neural circuits in neurological disorders; Develop treatments for previously untreatable diseases; Utilize machine learning for therapeutic discovery; Implement genome editing techniques; Leverage bioelectronic medicine for treatment solutions
How much Exin Therapeutics raised
Pre-Seed - $500,000
January 21, 2025Lead Investor: Y Combinator
Other Considerations
Backed by Y Combinator; Focused on addressing unmet medical needs in neurology; Active in the biotechnology sector
See something that needs updating? Suggest edits to this profile.